Back

Impact on adverse events of guideline-directed medical therapy for heart failure in patients with a systemic right ventricle

31 August 2025 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Adult congenital heart disease: medical treatment Adult Congenital Heart Disease (ACHD) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Ippolita Altobelli

AORN Ospedali dei Colli - Monaldi Hospital, Naples (Italy)

8 More presentations in this session

Presentation thumbnail
Dapagliflozin prevents fibrogenic activation in endocardial endothelial cells under altered flow
Ms J. Gaal (Boston, US) Doctor I. Friehs (Boston, US)
Abstract Slides Video
Presentation thumbnail
Sodium-glucose cotransporter 2 inhibitors for the treatment of single ventricle circulatory failure in adults with congenital heart disease
Doctor R. Neijenhuis (Leiden, NL)
Abstract Slides Video
Presentation thumbnail
Results of CHASM IN ACHD (peer CoacHing Adaptive Self-Management INterventions for young Adults with Congenital Heart Disease) study
Doctor R. Krasuski (Durham, US)
Abstract Slides Video
Presentation thumbnail
Sacubitril/ valsartan in patients with congenital heart disease: a systematic review and meta-analysis
Doctor D. Ntiloudi (Pireas, GR)
Abstract Slides Video
Presentation thumbnail
Sodium-glucose cotransporter-2 inhibitor use in children with left ventricular systolic dysfunction: a matched case-control analysis
Doctor D. Newland (Seattle, US)
Abstract Slides Video

Access the full session

Session thumbnail
Adult congenital heart disease: medical treatment

The Event

Event poster

ESC Congress 2025

31 August 2025 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Management of heart failure in congenitally corrected transposition of the great arteries: medical and interventional strategies for the systemic right ventricle
thumbnail
Congress Presentation
Relationship between left ventricular reverse remodeling and guideline-directed medical therapy intensity in de novo heart failure with reduced ejection fraction patients: insight from TRANS-HF trial
thumbnail
Congress Presentation
Can heart failure guideline-directed medical therapy improve left ventricular assist device outcomes?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources